Key opinion leader trends, clinical-trial commentary, conference recaps, and AI-native intelligence on the physicians shaping oncology practice — straight from the social conversation.
Akeso biopharma published a preprint of the mechanism of action of ivonescimab. Can the KOL Pulse AI provide context to KOL questions about HARMONi-A?
On September 8th, HARMONI-2 trial data will be presented at World Lung by Akeso. In 2022, Summit, founded by Bob Duggan, bet $500M Cash and $5B Total that ivone…
On September 8th, HARMONI-2 trial data will be presented at World Lung by Akeso. In 2022, Summit, founded by Bob Duggan, bet $500M Cash and $5B Total that ivone…
KOL Pulse turns the oncology social conversation into AI-native intelligence. See it in action.